But many panel members said J. & J. recipients might also benefit from the option of a Pfizer-BioNTech or Moderna booster, an action that an F.D.A. official said was possible.
Published: October 16, 2021 at 02:02AM
from NYT Health https://ift.tt/3FQF4EG